New Horizons in the treatment and Management of Relapsed/Refractory Multiple Myeloma: What Managed Care Needs to Know About Emerging Therapies

A continuing medical education activity sponsored by NAMCP and AAMCN

This webinar series will provide critical updates on the advances in the management of Multiple Myeloma

These are archives of live webinars held between April 28 to May 8, 2020.
If you participated in any of the live webinars, you are not eligible to claim credit from the archive of that webinar.

By clicking on each of the titles, you will be able to participate in each part.
It is not required that you participate in all three or in order.

Each session has its own specific valid dates

This series is supported by an educational grant from
Sanofi Genzyme

 

 Audience: This activity is intended for healthcare professionals practicing in managed care environments.

 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

Description:
Multiple Myeloma (MM) accounts for 10% of hematologic malignancies. In 2020, it is estimated that MM will be responsible for 12,960 new deaths and 32,110 new cases. In recent years, more treatments have become available that have increased survival numbers significantly, though prognosis still remains rather poor, especially in relapsed/refractory (R/R) disease. Fortunately for patients with R/R MM, there are several novel options that have been recently approved or are currently undergoing late stage clinical trials that have shown great promise in their ability to improve clinical outcomes.


A Deeper Look into Emerging Therapies in the Management of Relapsed/Refractory Multiple Myeloma: What Does Recent Clinical Trial Data Have to Say?

  1. Identify current unmet clinical needs in the diagnosis and management of relapsed/refractory multiple myeloma
  2. Summarize new evidence on the treatment role, efficacy, and safety of novel agent classes and next-generation therapeutics for patients with relapsed or refractory multiple myeloma
  3. Analyze the role of emerging anti-CD38 monoclonal antibodies in the relapsed/refractory multiple myeloma treatment paradigm
  4. Explore strategies for sequencing treatment for patients with relapsed/refractory multiple myeloma using novel agents
  5. Identify patients with relapsed/refractory multiple myeloma for whom a next-generation therapeutic is an appropriate choice for the next step in the management of their cancer
          Physician, Nursing and CMCN credits valid to May 1, 2022

Improving Patient Adherence and Quality of Life in Relapsed/Refractory Multiple Myeloma: Anticipating and Managing Adverse Events Associated with Emerging Therapies

  1. Compare emerging therapies in relapsed/refractory multiple myeloma, including mechanisms of action, delivery methods, dosing and scheduling, efficacy, safety, interactions, and ease of use
  2. Identify adverse events associated with emerging therapies in relapsed/refractory multiple myeloma, and select appropriate strategies to help ensure patient treatment adherence and optimal quality of life
  3. Discuss methods to communicate effectively with cancer patients and the multidisciplinary team to understand and address the needs of each patient around emerging therapies in RRMM and improve treatment adherence, quality of life, and survival outcomes
  4. Review how treatment strategies can be affected by adverse events based on patientís individualized needs
  5. Analyze strategies to monitor and manage adverse events associated with emerging anti-CD38
          Physician, Nursing and CMCN credits valid to May 1, 2022

What Managed Care Needs to Know about Emerging Therapies in the Management of Relapsed/Refractory Multiple Myeloma

  1. Identify current unmet economic needs in the management of relapsed/refractory multiple myeloma
  2. Assess recent clinical data and managed care considerations of next generation therapies and where these agents fit into the current relapsed/refractory multiple myeloma management paradigm
  3. Examine the managed care considerations of emerging anti-CD38 therapies by exploring where these potential agents may fit into current the relapsed/refractory multiple myeloma management paradigm
  4. Address payer-and provider-related barriers to appropriate evidence-based use of emerging anti-CD38 therapies
          Physician, Nursing and CMCN credits valid to May 1, 2022